Herbal Compounds in the Treatment of Pulmonary Silicosis

Adamcakova, Jana; Mokrá, Daniela

doi:10.33549/10.33549/physiolres.934817

Cited by 3 publications

(2 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetrandrine, which has been approved to treat silicosis in China [ 49 ], can inhibit lung inflammation and lung fibrosis to improve pulmonary function [ 50 ]. In recent years, herbal compounds have been documented to trigger the generation of ROS, suppress the activation of inflammasomes, and exhibit anti-inflammatory and antifibrotic effects [ 51 ]. Clinical trials have shown that patients' lung function, quality of life, and exercise ability have significantly improved after treatment with traditional Chinese medicines [ 52 ].…”

Section: Treatment For Silicosismentioning

confidence: 99%

Early Identification, Accurate Diagnosis, and Treatment of Silicosis

Yang

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

Silicosis is a global problem, and it has brought about great burdens to society and patients’ families. The etiology of silicosis is clear, preventable, and controllable, but the onset is hidden and the duration is long. Thus, it is difficult to diagnose it early and treat it effectively, leaving workers unaware of the consequences of dust exposure. As such, a lack of details in the work history and a slow progression of lung disease contribute to the deterioration of patients until silicosis has advanced to fibrosis. These issues are the key factors impeding the diagnosis and the treatment of silicosis. This article reviews the literature on the early identification, diagnosis, and treatment of silicosis as well as analyzes the difficulties in the diagnosis and the treatment of silicosis and discusses its direction of future development.

show abstract

Section: Treatment For Silicosismentioning

confidence: 99%

Early Identification, Accurate Diagnosis, and Treatment of Silicosis

Yang

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Nevertheless, despite a huge progress in understanding the complex interactions among the proinflammatory, prooxidant and profibrotic mechanisms in the pathogenesis of lung silicosis in the last years, there is still a lack of effective therapy. Various anti-inflammatory, antioxidant, and anti-fibrotic treatments including herbal compounds have been tested in experimental models of lung silicosis as well as in patients suffering from lung silicosis; however, effects of the given treatments were often contradictory (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Effects of early dexamethasone treatment on several markers of inflammation and fibrosis in an animal model of lung silicosis in rats – A pilot study

Adamcakova

Bálentová

Hanusrichterova

et al. 2022

Acta Medica Martiniana

View full text Add to dashboard Cite

Lung silicosis is primarily caused by inhalation of particles of silicon oxide (silica). Despite a huge progress in understanding the interactions among the pathomechanisms of lung silicosis in the last years, there is a lack of effective therapy. With respect to a wide therapeutic action of corticosteroids, the purpose of this pilot study was to evaluate early effects of dexamethasone on several markers of inflammation and lung fibrosis in a rat model of silicosis. The silicosis model was induced by a single transoral intratracheal instillation of silica (50 mg/ml/animal), while the controls received an equivalent volume of sterile saline. The treatment with intraperitoneal dexamethasone initiated the next day after the silica instillation and was given 2-times a week at a dose of 1 mg/kg, while the controls received an equivalent volume of saline. The animals were euthanized 14 or 28 days after the treatment onset. Total and differential counts of leukocytes in the blood and bronchoalveolar lavage (BAL) fluid were determined. The presence of collagen in the bronchioles and lung vessels was detected by Sirius red staining and a smooth muscle mass was detected by smooth muscle actin. In comparison to saline, the instillation of silica increased the total count of circulating leukocytes after 14 and 28 days of the experiment (both p<0.05), which was associated with higher counts of lymphocytes (p<0.05 after 14 days, p>0.05 after 28 days) and slight but non-significant increases in neutrophils and eosinophils (both p>0.05). Although the total cell count in the BAL fluid did not change significantly, the percentages and absolute counts of neutrophils, eosinophils, and lymphocytes (p<0.05, p<0.01 or p<0.001) elevated after 14 and 28 days of the experiment. Silica induced an accumulation of collagen in the bronchioles (p<0.001 after both 14 and 28 days) and pulmonary vessels (p<0.01 after both 14 and 28 days) and elevated a formation of smooth muscle mass (p<0.05 after 14 days, p<0.01 or p<0.001 after 28 days). Treatment with dexamethasone decreased circulating leukocytes (p<0.01) and lymphocytes (p<0.001) and increased neutrophils (p<0.05), which was associated with a slightly decreased total cell count in BAL (p>0.05), decline in lymphocytes (p<0.01), and slight decreases in neutrophils and eosinophils after 28 days of the treatment. Moreover, dexamethasone reduced the accumulation of collagen (p<0.01 after 14 days and p<0.001 after 28 days) and the formation of smooth muscle mass (p<0.01 for bronchioles and p>0.05 for vessels after 24 days, p<0.001 for both bronchioles and vessels after 28 days). In conclusion, early dexamethasone treatment mitigated silica-induced granulocytic-lymphocytic inflammation and decreased a formation of collagen and smooth muscle mass in the bronchiolar and vascular walls, demonstrating a therapeutic potential of dexamethasone in the lung silicosis.

show abstract

What is a Therapeutic Potential of N-Acetylcysteine in Lung Silicosis?

Adamcakova

Mokrá

2021

Acta Medica Martiniana

View full text Add to dashboard Cite

Lung silicosis is a serious pulmonary disease caused by an exposure of lung to inhaled silicon dioxide (SiO2) or silica. Although pathomechanisms of the disease have not been fully elucidated, oxidative stress has been recognized as a fundamental factor triggering a fibrotizing inflammation leading to irreversible changes in lung tissue. Based on this knowledge, therapeutic potential of various antioxidants has been intensively discussed. Among them, N-acetylcysteine with its multiple anti-inflammatory and antioxidant actions and a long-term experience with its clinical use in various diseases appears as a very promising choice. The purpose of this article is to review the therapeutic effects of N-acetylcysteine particularly in relation to a lung injury and to point out a potential of N-acetylcysteine in the treatment of lung silicosis.

show abstract

Herbal Compounds in the Treatment of Pulmonary Silicosis

Cited by 3 publications

References 91 publications

Early Identification, Accurate Diagnosis, and Treatment of Silicosis

Early Identification, Accurate Diagnosis, and Treatment of Silicosis

Effects of early dexamethasone treatment on several markers of inflammation and fibrosis in an animal model of lung silicosis in rats – A pilot study

What is a Therapeutic Potential of N-Acetylcysteine in Lung Silicosis?

Contact Info

Product

Resources

About